Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CTLA-4
Biotech
UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data
UroGen is handing back an anti-CTLA-4 antibody after concluding that phase 1 data for the bladder cancer drug didn’t warrant further development.
James Waldron
Nov 6, 2025 10:00am
Instil refills pipeline in $2B biobucks deal with ImmuneOnco
Aug 1, 2024 10:19am
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Mar 12, 2024 7:07am
Agenus lays off 25%, sidelines programs to focus on cancer combo
Aug 23, 2023 11:04am
BioNTech's $200M bet on next-gen Yervoy triggers tumor responses
Jun 2, 2023 10:00am
ESMO: AstraZeneca's bispecific shows promise but limited by dose
Sep 11, 2022 4:20am
